Viruses, Vol. 16, Pages 661: T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy

Viruses, Vol. 16, Pages 661: T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy Viruses doi: 10.3390/v16050661 Authors: Sneha Datwani Rebecca Kalikawe Rachel Waterworth Francis M. Mwimanzi Richard Liang Yurou Sang Hope R. Lapointe Peter K. Cheung Fredrick Harrison Omondi Maggie C. Duncan Evan Barad Sarah Speckmaier Nadia Moran-Garcia Mari L. DeMarco Malcolm Hedgcock Cecilia T. Costiniuk Mark Hull Marianne Harris Marc G. Romney Julio S. G. Montaner Zabrina L. Brumme Mark A. Brockman People living with HIV (PLWH) can exhibit impaired immune responses to vaccines. Accumulating evidence indicates that PLWH, particularly those receiving antiretroviral therapy, mount strong antibody responses to COVID-19 vaccines, but fewer studies have examined cellular immune responses to the vaccinations. Here, we used an activation-induced marker (AIM) assay to quantify SARS-CoV-2 spike-specific CD4+ and CD8+ T cells generated by two and three doses of COVID-19 vaccines in 50 PLWH receiving antiretroviral therapy, compared to 87 control participants without HIV. In a subset of PLWH, T-cell responses were also assessed after post-vaccine breakthrough infections and/or receipt of a fourth vaccine dose. All participants remained SARS-CoV-2 infection-naive until at least one month after their third vaccine dose. SARS-CoV-2 infection was determined by seroconversion to a Nucleoc...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research